Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GH21 capsules plus osimertinib in EGFR‑mutant advanced NSCLC (Phase Ib/II)
CTR20234079Phase 2Active
- Sponsor
- Genhouse Bio
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GH21 in non-small cell lung cancer (NSCLC), sponsored by Genhouse Bio. Started Mar 2024; status: active.
02
Drugs
GH21
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20234079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234079.